Abstract
Purpose
To examine the mechanisms of the alteration of serum uric acid level by angiotensin II receptor blockers (ARBs), the effects of ARBs on renal uric acid transporters, including OAT1, OAT3, OAT4, and MRP4, were evaluated.
Materials and Methods
Uptakes of uric acid by OAT1-expressing Flp293 cells, by Xenopus oocytes expressing OAT3 or OAT4, and by membrane vesicles from Sf9 cells expressing MRP4 were evaluated in the presence or absence of ARBs.
Results
All ARBs inhibited uptake of uric acid or estrone-3-sulfate by OAT1, OAT3 and OAT4 in concentration dependent manners. Among them, the IC50 values of valsartan, olmesartan and pratosartan for OAT3 were comparable to clinically observed unbound maximum plasma concentration of ARBs. Candesartan, losartan, and telmisartan inhibited ATP-dependent uptake of uric acid by MRP4 at 10 μM. The IC50 value of losartan for MRP4 was comparable to the estimated kidney tissue concentration of losartan. No ARBs showed trans-stimulatory effects on the uptake of estrone-3-sulfate by OAT4.
Conclusion
Valsartan, olmesartan, and pratosartan could inhibit the OAT3-mediated uric acid secretion in clinical situations. Furthermore losartan could inhibit ATP-dependent uric acid secretion by MRP4. These effects may explain partially the alteration of serum uric acid level by ARBs.
Similar content being viewed by others
Abbreviations
- ARB:
-
angiotensin II receptor blocker
- E13S:
-
estrone-3-sulfate
- MRP:
-
multidrug resistance-associated protein
- OAT:
-
organic anion transporter
- SUA:
-
serum uric acid
- URAT1:
-
uric acid transporter
References
M. H. Alderman, H. Cohen, S. Madhavan, and S. Kivlighn. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34:144–150 (1999).
P. Verdecchia, G. Schillaci, G. Reboldi, S. C. Santeusanio, C. Porcellati, and P. Brunetti. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36:1072–1078 (2000).
A. J. Manolis, E. Grossman, B. Jelakovic, A. Jacovides, D. C. Bernhardi, W. J. Cabrera, L. A. Watanabe, J. Barragan, N. Matadamas, A. Mendiola, K. S. Woo, J. R. Zhu, A. D. Mejia, T. Bunt, T. Dumortier, and R. D. Smith. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin. Ther. 22:1186–1203 (2000).
W. J. Elliott, D. A. Calhoun, P. T. DeLucca, L. P. Gazdick, D. E. Kerns, and R. K. Zeldin. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin. Ther. 23:1166–1179 (2001).
M. Nakashima, T. Uematsu, K. Kosuge, and M. Kanamaru. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. 42:333–335 (1992).
M. Burnier, B. Rutschmann, J. Nussberger, J. Versaggi, S. Shahinfar, B. Weaber, and H.R. Brunner salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22:339–347 (1993).
J. P. Fauvel, S. Velon, N. Berra, N. Pozet, O. Madonna, P. Zech, and M. Laville. Effects of losartan on renal function in patients with essential hypertension. J. Cardiovasc. Pharmacol. 28:259–263 (1996).
R. W. Rundles. The development of allopurinol. Arch. Intern. Med. 145:1492–1503 (1985).
D. A. Sica and A. C. Schoolwerth. Chapter 16, Renal handling of organic anions and cations: Excretion of uric acid. In B. M. Brenner (ed.), The Kidney, 6th edn, Saunders, Philadelphia, 2000, pp. 680–700.
M. A. Hediger, R. J. Johnson, H. Miyazaki, and H. Endou. Molecular physiology of urate transport. Physiology 20:125–133 (2005).
A. Enomoto, H. Kimura, A. Chairoungdua, Y Shigeta, P. Jutabha, S. H. Cha, M Hosoyamada, M. Takeda, T. Sekine, T. Igarashi, H. Matsuo, Y. Kikuchi, T. Oda, K. Ichida, T. Hosoya, K. Shimokata, T. Niwa, Y. Kanai, and H. Endou. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447–452 (2002).
Y. Hagos, D. Stein, B. Ugele, G. Burckhardt, and A. Bahn. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J. Am. Soc. Nephrol. 18:430–437 (2007).
K. Icida, M. Hosoyamada, H. Kimura, M. Takeda, Y. Utsunomiya, T. Hosoya, and H. Endou. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int. 63:143–155 (2003).
S. H. Cha, T. Sekine, J. Fukushima, Y. Kanai, Y. Kobayashi, T. Goya, and H. Endou. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59:1277–1286 (2001).
R. A. M. H. van Aubel, P. H. E. Smeets, J. J. M. W. van den Heuvel, and F. G. M. Russel. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal. Physiol. 288:F327–F333 (2004).
N. Ishiguro, A. Saito, K. Yokoyama, M. Morikawa, T. Igarashi, and I Tamai. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab. Dispos. 33:495–499 (2005).
A Tsuji, A. Sakata, and I Tamai. Tissue distribution of the multidrug-resistance gene product P-glycoprotein and its physiological function. Nippon Rinsho 55:1059–1063 (1997).
R. Ohashi, I Tamai, H. Yabuuchi, J. Nezu, A. Oku, Y. Sai, M. Shimane, and A. Tsuji. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther. 291:778–784 (1999).
T. Iwanaga, M. Sato, T. Maeda, T. Ogihara, and I Tamai. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J. Pharmacol. Exp. Ther. 320:211–217 (2007).
M. Hosoyamada, T. Sekine, Y. Kanai, and H. Endou. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276:F122–F128 (1999).
E. R. Liman, J. Tytgat, and P. Hess. Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs. Neuron 9:861–871 (1992).
T. Iwanaga, D. Kobayashi, M. Hirayama, T. Maeda, and I. Tamai. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab. Dispos. 33:1791–1795 (2005).
M. Tsuda-Tsukimoto, T. Maeda, T. Iwanaga, T. Kume, and I Tamai. Characterization of hepatobiliary transport systems of a novel α4β1/α4β7 dual antagonist, TR-14035. Pharm. Res. 23:2646–2656 (2006).
M. Rius, A. T. Nies, J. Hummel-Eisenbeiss, G. Jedlitschky, and D. Keppler. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 38:374–384 (2003).
F. Yamashita, H. Ohtani, N. Koyabu, F. Ushigome, H. Satoh, H. Murakami, T. Uchiumi, T. Nakamura, M. Kuwano, M. Tsujimoto, and Y. Sawada. Inhibitory effect of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic transporter 4. J. Pharm. Pharmacol. 58:1499–1505 (2006).
H. Uchino, I Tamai, K. Yamashita, Y. Minemoto, Y. Sai, H. Yabuuchi, K. Miyamoto, E. Takeda, and A Tsuji. p-Aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem. Biophys. Res. Commun. 270:254–259 (2000).
Acknowledgment
This study was supported in part by a Grant in Aid for Scientific Research from The Ministry of Education, Culture, Sports, Science, and Technology, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sato, M., Iwanaga, T., Mamada, H. et al. Involvement of Uric Acid Transporters in Alteration of Serum Uric Acid Level by Angiotensin II Receptor Blockers. Pharm Res 25, 639–646 (2008). https://doi.org/10.1007/s11095-007-9401-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-007-9401-6